Molecular Partners AG
Index- P/E2.02 EPS (ttm)3.40 Insider Own- Shs Outstand32.32M Perf Week-4.85%
Market Cap222.33M Forward P/E89.09 EPS next Y0.08 Insider Trans- Shs Float26.74M Perf Month-50.61%
Income113.70M PEG- EPS next Q-1.04 Inst Own4.70% Short Float0.03% Perf Quarter-69.87%
Sales186.60M P/S1.19 EPS this Y18.10% Inst Trans14.59% Short Ratio0.42 Perf Half Y-34.35%
Book/sh8.41 P/B0.82 EPS next Y-98.47% ROA51.00% Target Price34.47 Perf Year-
Cash/sh9.40 P/C0.73 EPS next 5Y- ROE70.10% 52W Range5.92 - 32.04 Perf YTD-64.23%
Dividend- P/FCF2.07 EPS past 5Y- ROI-55.90% 52W High-78.59% Beta-
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low15.88% ATR0.71
Employees163 Current Ratio10.00 Sales Q/Q16.80% Oper. Margin61.10% RSI (14)25.00 Volatility5.03% 5.73%
OptionableNo Debt/Eq0.02 EPS Q/Q443.90% Profit Margin60.90% Rel Volume3.80 Prev Close6.88
ShortableYes LT Debt/Eq0.02 Earnings- Payout0.00% Avg Volume21.65K Price6.86
Recom2.00 SMA20-2.92% SMA50-53.86% SMA200-63.67% Volume82,146 Change-0.34%
May-25-22Upgrade Credit Suisse Underperform → Neutral
Apr-27-22Downgrade Credit Suisse Neutral → Underperform
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
May-12-22 04:05PM  
May-11-22 01:00AM  
May-03-22 12:00PM  
Apr-27-22 08:02AM  
Apr-26-22 04:05PM  
Apr-23-22 01:00AM  
Apr-13-22 12:00PM  
Mar-24-22 02:00AM  
Mar-17-22 01:00AM  
Mar-15-22 04:30PM  
Feb-25-22 04:30PM  
Feb-11-22 04:10PM  
Feb-10-22 07:13AM  
Jan-28-22 05:57AM  
Jan-23-22 02:28AM  
Jan-18-22 01:00AM  
Jan-13-22 05:00PM  
Jan-12-22 10:13AM  
Jan-11-22 11:37AM  
Jan-10-22 06:51PM  
Jan-06-22 10:00AM  
Jan-05-22 04:05PM  
Dec-15-21 01:00AM  
Dec-14-21 12:16PM  
Dec-12-21 04:00PM  
Dec-09-21 01:00AM  
Dec-06-21 01:00AM  
Dec-03-21 01:00AM  
Nov-30-21 12:48PM  
Nov-24-21 01:00AM  
Nov-16-21 06:49AM  
Nov-04-21 02:00AM  
Oct-28-21 01:00AM  
Oct-20-21 01:00AM  
Sep-03-21 04:05PM  
Aug-26-21 01:00AM  
Aug-09-21 01:00AM  
Jul-13-21 06:55AM  
Jul-08-21 09:04AM  
Jun-15-21 10:00PM  
Jun-13-21 04:00PM  
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.